BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15571383)

  • 1. Cell-specific delivery of a chemotherapeutic to lung cancer cells.
    Zhou X; Chang YC; Oyama T; McGuire MJ; Brown KC
    J Am Chem Soc; 2004 Dec; 126(48):15656-7. PubMed ID: 15571383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel peptide probe for imaging and targeted delivery of liposomal doxorubicin to lung tumor.
    He X; Na MH; Kim JS; Lee GY; Park JY; Hoffman AS; Nam JO; Han SE; Sim GY; Oh YK; Kim IS; Lee BH
    Mol Pharm; 2011 Apr; 8(2):430-8. PubMed ID: 21222482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery.
    Lee TY; Lin CT; Kuo SY; Chang DK; Wu HC
    Cancer Res; 2007 Nov; 67(22):10958-65. PubMed ID: 18006841
    [TBL] [Abstract][Full Text] [Related]  

  • 4. targeted drug delivery to hepatocarcinoma in vivo by phage-displayed specific binding peptide.
    Du B; Han H; Wang Z; Kuang L; Wang L; Yu L; Wu M; Zhou Z; Qian M
    Mol Cancer Res; 2010 Feb; 8(2):135-44. PubMed ID: 20145035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer.
    Moura V; Lacerda M; Figueiredo P; Corvo ML; Cruz ME; Soares R; de Lima MC; Simões S; Moreira JN
    Breast Cancer Res Treat; 2012 May; 133(1):61-73. PubMed ID: 21805188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer activity of PEGylated matrix metalloproteinase cleavable peptide-conjugated adriamycin against malignant glioma cells.
    Lim SH; Jeong YI; Moon KS; Ryu HH; Jin YH; Jin SG; Jung TY; Kim IY; Kang SS; Jung S
    Int J Pharm; 2010 Mar; 387(1-2):209-14. PubMed ID: 19945519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo.
    Song S; Liu D; Peng J; Sun Y; Li Z; Gu JR; Xu Y
    Int J Pharm; 2008 Nov; 363(1-2):155-61. PubMed ID: 18692120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted magnetic liposomes loaded with doxorubicin.
    Pradhan P; Banerjee R; Bahadur D; Koch C; Mykhaylyk O; Plank C
    Methods Mol Biol; 2010; 605():279-93. PubMed ID: 20072888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment.
    Hyung W; Ko H; Park J; Lim E; Park SB; Park YJ; Yoon HG; Suh JS; Haam S; Huh YM
    Biotechnol Bioeng; 2008 Feb; 99(2):442-54. PubMed ID: 17625788
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent retro-inverso D-peptide for simultaneous targeting of angiogenic blood vasculature and tumor cells.
    Li Y; Lei Y; Wagner E; Xie C; Lu W; Zhu J; Shen J; Wang J; Liu M
    Bioconjug Chem; 2013 Jan; 24(1):133-43. PubMed ID: 23241015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular drug delivery by sulfatide-mediated liposomes to gliomas.
    Shao K; Hou Q; Duan W; Go ML; Wong KP; Li QT
    J Control Release; 2006 Oct; 115(2):150-7. PubMed ID: 16963144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening and identification of a peptide specifically targeted to NCI-H1299 from a phage display peptide library.
    Zang L; Shi L; Guo J; Pan Q; Wu W; Pan X; Wang J
    Cancer Lett; 2009 Aug; 281(1):64-70. PubMed ID: 19327883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD19-targeted liposomal doxorubicin improves the therapeutic efficacy in murine B-cell lymphoma and ameliorates the toxicity of liposomes with varying drug release rates.
    Allen TM; Mumbengegwi DR; Charrois GJ
    Clin Cancer Res; 2005 May; 11(9):3567-73. PubMed ID: 15867261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Galactosylated α,β-poly[(2-hydroxyethyl)-L-aspartamide]-bound doxorubicin: improved antitumor activity against hepatocellular carcinoma with reduced hepatotoxicity.
    Cheng X; Gao F; Xiang J; Jiang X; Chen J; Zhang J
    Anticancer Drugs; 2011 Feb; 22(2):136-47. PubMed ID: 20966743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
    Li X; Ding L; Xu Y; Wang Y; Ping Q
    Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant enhancement of antitumor activity and bioavailability of intracellular pH-sensitive polymeric micelles by folate conjugation.
    Bae Y; Kataoka K
    J Control Release; 2006 Nov; 116(2):e49-50. PubMed ID: 17718965
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of elastin-like polypeptide for thermally targeted delivery of doxorubicin.
    Bidwell GL; Fokt I; Priebe W; Raucher D
    Biochem Pharmacol; 2007 Mar; 73(5):620-31. PubMed ID: 17161827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vascular targeting with phage peptide libraries.
    Pasqualini R
    Q J Nucl Med; 1999 Jun; 43(2):159-62. PubMed ID: 10429511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular delivery of peptide nucleic acid by cell-penetrating peptides.
    Kilk K; Langel U
    Methods Mol Biol; 2005; 298():131-41. PubMed ID: 16044544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.
    Wong HL; Bendayan R; Rauth AM; Xue HY; Babakhanian K; Wu XY
    J Pharmacol Exp Ther; 2006 Jun; 317(3):1372-81. PubMed ID: 16547167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.